ClinicalTrials.gg
TerminatedNCT03250299Updated Jun 24, 2024Results posted

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

A Phase 1 interventional study of Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Glioblastoma and MGMT-Unmethylated Glioblastoma, sponsored by Basilea Pharmaceutica. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Treatment

Why this study was terminated
Due to the National Cancer Institute's (NCI)-mandated termination of the Adult Brain Tumor Consortium which was conducting the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
677th of 1,155
26 · median 33
Started
2017
with 54 others
Phase 1
481 of 1,302
70 open now
Registered
803rd of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 677th largest by enrollment of the 1,155 interventional ones that give a count, is one of 55 that started in 2017, is one of 481 in phase 1, and was the 803rd registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT) promoter unmethylated glioblastoma (GBM). Drugs used in chemotherapy, such as microtubule-targeted agent BAL101553, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving microtubule-targeted agent BAL101553 and radiation therapy may work better in treating patients with GBM.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of microtubule-targeted agent BAL101553 (BAL101553) in combination with standard radiation in patients with newly diagnosed MGMT promoter unmethylated GBM.

SECONDARY OBJECTIVES:

I. To estimate safety and tolerability of the combination of BAL101553 in combination with standard radiation in patients with newly diagnosed MGMT promoter unmethylated GBM.

II. To determine overall and progression-free survival.

OUTLINE: This was a dose escalation study of the microtubule-targeted agent BAL101553.

Patients received BAL101553 orally (PO) once daily (QD) for 6 weeks, concurrent with standard radiation therapy (RT) 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.

This treatment period was followed by a 4-week no-treatment period. The duration of study treatment was defined as these 6 weeks of treatment plus the 4 weeks of rest.

The safety evaluation period was the 10 weeks from start of treatment

After completion of study treatment, patients were followed up at 30 days, and then every 2 months for 2 years and then every 6 months thereafter.

03

Conditions studied

  • Glioblastoma
  • MGMT-Unmethylated Glioblastoma

Keywords

  • Glioblastoma
  • Brain tumor
  • Lisavanbulin
  • BAL101553
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

The following inclusion criteria were applied:

  • Patients must have had -proven GBM
  • Patients must have recovered from the immediate post-operative period
  • Patients must have had tumor MGMT methylation status of unmethylated as determined by local pathologist using a Clinical Laboratory Improvement Act (CLIA)-approved diagnostic test; results of routinely-used methods for MGMT methylation testing (e.g. methylation-specific [MS]- polymerase chain reaction [PCR] or quantitative PCR) were acceptable
  • Patients must have been be able to undergo magnetic resonance imaging (MRI) of the brain with gadolinium
  • Patients must not have received prior radiation therapy (RT), chemotherapy, immunotherapy or therapy with a biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy), or hormonal therapy for their brain tumor; therapy is allowed
  • Patients must have had a tumor tissue form indicating availability of archived tissue from initial resection at diagnosis of GBM, completed and signed by a pathologist
  • Patients must have had a performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
  • >= 1,500/micro liter (mcL)
  • >= 100,000/mcL
  • >= 9 g/dL
  • Total =\< 1.5 x institutional (ULN), unless the patient has known Gilbert's syndrome
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 2.5 x ULN
  • Creatinine =\< 1.5 x ULN
  • >= 60 mL/min/1.73 m\^2 for patients with creatinine levels > ULN
  • (APTT)/partial thromboplastin time (PTT) =\< 1.5 x ULN
  • Sodium >= 130 mmol/L
  • Patients must have been able to provide written
  • Patients must have had baseline MRI performed within the 21 days prior to starting treatment
  • Women of must have had a negative serum pregnancy test within 72 hours prior to the first dose of BAL101553; women of childbearing potential must have agreed to use highly-effective methods for the duration of study participation and for an additional 90 days after the last dose of study drug; highly-effective contraceptive methods include male or female sterilization (bilateral tubal occlusion or vasectomy); intrauterine device (IUD); combined (estrogen- and progesterone-containing) hormonal contraception (oral, vaginal ring or transdermal patch) with an ethinylestradiol dose of at least 30 ug, plus use of male condoms (preferably with spermicides), female condoms, a female diaphragm or a cervical cap; or total sexual abstinence; if a woman became pregnant or suspected she was pregnant while participating in this study, she was asked to inform her treating physician immediately; male patients must have agreed not to donate sperm from the time of the first dose of study drug until 90 days after the end of treatment; male patients, without a vasectomy and with a partner of childbearing potential, must have agreed to use condoms during the study and for at least 90 days after the end of treatment; the patient should have been instructed that their female partner should use another form of contraception for the duration of the study and continue this use for at least 90 days after the last dose of study drug
  • Patients must have had no concurrent except curatively-treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must have been disease-free for >= 5 years
  • Patients must have been maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the start of treatment
  • Patients must have been able to swallow whole capsules

The following exclusion criteria were applied:

  • Patients receiving any other agent
  • Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BAL101553
  • Patients on drugs that are strong inhibitors and/or inducers of CYP2C9, CYP2C19 or (including enzyme-inducing anti-epileptic drugs EIAEDs]), were not eligible for the study; patients taking non-EIAEDs were permitted to take part in the study; patients previously treated with any of the prohibited concomitant medications listed above may have been enrolled if they had been off the medication for >= 10 days prior to the first dose of BAL101553
  • Patients may not have been on coumarin anti-coagulants (warfarin, etc.); heparin, low-molecular weight heparin (LMWH), or other antithrombotic medications were permitted
  • Patients with gastrointestinal disease, or those who had a procedure that was expected to interfere with the oral absorption or tolerance of BAL101553 (e.g., functionally-relevant gastrointestinal obstruction, or frequent vomiting unresolved upon anti-emetic supportive care)
  • Patients with peripheral neuropathy >= (CTCAE) grade 2
  • Patients with ataxia >= CTCAE grade 2
  • Patients with known acute or chronic or infection
  • Patients with systolic blood pressure (SBP) >= 140 mmHg or diastolic blood pressure (DBP) >= 90 mmHg at the screening visit were ineligible; patients with an initial clinic blood pressure (BP) >= 140/90 mmHg may be included if SBP \< 140 mmHg and DBP \< 90 mmHg is confirmed in two subsequent BP measurements on the same day
  • Patients with BP combination treatment with more than two antihypertensive medications were ineligible
  • Significant cardiac disease or abnormality, including any of the following:

    • \< 50% at screening (assessed by echocardiography, cardiac MRI or multigated acquisition [MUGA])
    • Fridericia's correction formula (QTcF) > 470 ms on screening (ECG), or a clinically-relevant ECG abnormality
    • Congenital long QT syndrome
    • History of sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes
    • Presence of atrial fibrillation with tachyarrhythmia (ventricular response rate > 100 beats per minute [bpm])
    • Bradycardia (heart rate \< 50 bpm)
    • Complete left bundle branch block.
    • Bifascicular block (complete right bundle branch block and anterior or posterior left hemiblock)
    • Myocardial infarction, acute coronary syndrome (including unstable angina), coronary revascularization procedures, or coronary arterial bypass grafting within the 6 months prior to starting study drug
    • Cardiac troponin (either troponin T or troponin I) > ULN
    • Congestive heart failure of class III or IV
    • Unstable angina pectoris
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements, were ineligible
  • Pregnant women were excluded from this study; breastfeeding should have been discontinued if the mother was treated with BAL101553
  • (HIV)-positive patients on combination antiretroviral therapy were ineligible
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Dose Finding

    Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.

    Drug: Microtubule-Targeted Agent BAL101553 · Radiation: Radiation Therapy

Interventions

  • Given PO

    Also known as: BAL101553, Microtubule-targeted Agent BAL101553

  • RadiationRadiation Therapy

    Undergo radiation therapy

    Also known as: Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation, radiation therapy, Radiation Therapy, Radiotherapeutics, radiotherapy, Radiotherapy, RT, Therapy, Radiation

06

What researchers measure

Primary outcomes

  1. Number of Patients With Dose-Limiting Toxicities (DLTs) for Each Maximal Tolerated Dose (MTD)-Determining Dose Cohort

    A DLT was defined as a clinically-significant adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications. Any DLT had to be a toxicity considered at least possibly related to BAL101553 or the combination of BAL101553 and radiation.

    Time frame: Up to 10 weeks

Secondary outcomes

  1. Number of Patients With Grade 3 to Grade 5 Adverse Events (AEs)

    Common Terminology Criteria for Adverse Events (CTCAE) displayed by increasing severity grades 3 to 5 (CTCAE grade 3/4/5 )

    Time frame: up to 10 weeks

  2. Overall Survival (OS) Time

    OS was defined as the time from Day 1 dosing to the date of death. Patients who have not died at study closure were censored at the time of last known alive.

    Time frame: Day 1 to date of death - up to 1679 days (4.6 years)

  3. Progression Free Survival (PFS) Time

    PFS was the interval between Day 1 dosing and the earliest date of progression. Progression was defined as: an increase in tumor size of more than 25% or the appearance of new lesions on MRI scans, significant clinical deterioration not attributable to causes other than the tumor, or death from any cause. Patients who have not progressed or died at study closure were censored at the time of their last assessment without progression.

    Time frame: Day 1 to date of disease progression - 1092 days (3.0 years)

07

Results

Posted Jun 24, 2024

Participant flow

Treatment was administered on an outpatient basis

BAL101553 4 mg Cohort
Participant flow — BAL101553 4 mg Cohort
MilestoneBAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg Cohort
Started50000
Completed50000
Not completed00000
BAL101553 6 mg Cohort
Participant flow — BAL101553 6 mg Cohort
MilestoneBAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg Cohort
Started05000
Completed04000
Not completed01000
Withdrew: Disease progression01000
BAL101553 8 mg Cohort
Participant flow — BAL101553 8 mg Cohort
MilestoneBAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg Cohort
Started00700
Completed00500
Not completed00200
Withdrew: Adverse event00100
Withdrew: Withdrawal by subject00100
BAL101553 12 mg Cohort
Participant flow — BAL101553 12 mg Cohort
MilestoneBAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg Cohort
Started00050
Completed00030
Not completed00020
Withdrew: Adverse event00020
BAL101553 15 mg Cohort
Participant flow — BAL101553 15 mg Cohort
MilestoneBAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg Cohort
Started00004
Completed00004
Not completed00000

Outcome measures

PrimaryNumber of Patients With Dose-Limiting Toxicities (DLTs) for Each Maximal Tolerated Dose (MTD)-Determining Dose Cohort

A DLT was defined as a clinically-significant adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications. Any DLT had to be a toxicity considered at least possibly related to BAL101553 or the combination of BAL101553 and radiation.

Time frame:
Up to 10 weeks
Reported as:
Number · participants
Number of Patients With Dose-Limiting Toxicities (DLTs) for Each Maximal Tolerated Dose (MTD)-Determining Dose Cohort
participantsBAL101553 4 mg MTD-determining CohortBAL101553 6 mg MTD-determining CohortBAL101553 8 mg MTD-determining CohortBAL101553 12 mg MTD-determining CohortBAL101553 15 mg MTD-determining Cohort
Number of Patients With Dose-Limiting Toxicities (DLTs) for Each Maximal Tolerated Dose (MTD)-Determining Dose Cohort00110
SecondaryNumber of Patients With Grade 3 to Grade 5 Adverse Events (AEs)

Common Terminology Criteria for Adverse Events (CTCAE) displayed by increasing severity grades 3 to 5 (CTCAE grade 3/4/5 )

Time frame:
up to 10 weeks
Reported as:
Count of participants · Participants
Number of Patients With Grade 3 to Grade 5 Adverse Events (AEs)
ParticipantsBAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg Cohort
Number of patients with only unrelated CTCAE Grade 3/4/5 AEs12121
Number of patients with related CTCAE Grade 3/4/5 AEs11110
Number of patients without CTCAE Grade 3/4/5 AEs32523
SecondaryOverall Survival (OS) Time

OS was defined as the time from Day 1 dosing to the date of death. Patients who have not died at study closure were censored at the time of last known alive.

Time frame:
Day 1 to date of death - up to 1679 days (4.6 years)
Reported as:
Median · Days
Overall Survival (OS) Time
DaysAll BAL101553 Treated Patients
Overall Survival (OS) Time383.0 (273.0 to 552.0)
SecondaryProgression Free Survival (PFS) Time

PFS was the interval between Day 1 dosing and the earliest date of progression. Progression was defined as: an increase in tumor size of more than 25% or the appearance of new lesions on MRI scans, significant clinical deterioration not attributable to causes other than the tumor, or death from any cause. Patients who have not progressed or died at study closure were censored at the time of their last assessment without progression.

Time frame:
Day 1 to date of disease progression - 1092 days (3.0 years)
Reported as:
Median · Days
Progression Free Survival (PFS) Time
DaysAll BAL101553 Treated Patients
Progression Free Survival (PFS) Time247.0 (128.0 to 366.0)

Adverse events

Collected over Adverse events (AEs) were collected for 10 weeks from start of treatment, All-cause Mortality monitored up to 1679 days (4.6 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BAL101553 4 mg Cohort5/5 (100%)2/5 (40%)5/5 (100%)
BAL101553 6 mg Cohort5/5 (100%)3/5 (60%)5/5 (100%)
BAL101553 8 mg Cohort4/7 (57.1%)2/7 (28.6%)7/7 (100%)
BAL101553 12 mg Cohort4/5 (80%)2/5 (40%)5/5 (100%)
BAL101553 15 mg Cohort0/4 (0%)1/4 (25%)4/4 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventBAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg Cohort
ConstipationGastrointestinal disorders0/50/50/70/51/4
SepsisInfections and infestations0/50/50/71/51/4
Urinary tract infectionInfections and infestations0/50/50/70/51/4
AphasiaNervous system disorders1/50/50/70/50/4
Brain oedemaNervous system disorders1/50/50/70/50/4
Cognitive disorderNervous system disorders0/51/50/70/50/4
DysarthriaNervous system disorders1/50/50/70/50/4
Facial paresisNervous system disorders1/50/50/70/50/4
HydrocephalusNervous system disorders0/51/50/70/50/4
LethargyNervous system disorders0/51/50/70/50/4
Most frequent other events
Showing 10 of 154
Most frequent other events
EventBAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg Cohort
Alanine aminotransferase increasedInvestigations1/51/52/74/52/4
FatigueGeneral disorders4/54/55/73/53/4
AnaemiaBlood and lymphatic system disorders1/51/53/71/53/4
Aspartate aminotransferase increasedInvestigations0/50/51/73/51/4
HeadacheNervous system disorders0/53/53/70/50/4
NauseaGastrointestinal disorders3/52/53/71/50/4
AlopeciaSkin and subcutaneous tissue disorders3/53/53/71/51/4
Muscular weaknessMusculoskeletal and connective tissue disorders1/52/50/73/51/4
HyperglycaemiaMetabolism and nutrition disorders0/53/51/73/50/4
HyponatraemiaMetabolism and nutrition disorders0/53/54/73/50/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg CohortTotal
<=18 years000000
Between 18 and 65 years3252214
>=65 years2323212
Age, Continuous
Age, Continuous(years)BAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg CohortTotal
Mean58.2 ± 10.5767.6 ± 6.2757.7 ± 11.2262.6 ± 12.1057.8 ± 13.4060.7 ± 10.71
Sex: Female, Male
Sex: Female, Male(Participants)BAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg CohortTotal
Female4243215
Male1332211
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg CohortTotal
Hispanic or Latino010001
Not Hispanic or Latino5365423
Unknown or Not Reported011002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg CohortTotal
American Indian or Alaska Native000000
Asian001001
Native Hawaiian or Other Pacific Islander000000
Black or African American000011
White5564323
More than one race000000
Unknown or Not Reported000101
Region of Enrollment
Region of Enrollment(participants)BAL101553 4 mg CohortBAL101553 6 mg CohortBAL101553 8 mg CohortBAL101553 12 mg CohortBAL101553 15 mg CohortTotal
United States5575426
08

Study locations

8 sites
  • UAB Comprehensive Cancer Center
    Birmingham, Alabama 35294-3410, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Wake Forest University Comprehensive Cancer Center
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • Abrams Cancer Center of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Hillman Cancer Center at University of Pittsburgh Cancer Institute
    Pittsburgh, Pennsylvania 15232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Jun 2022, 53 months.

Results were first posted in Jun 2024, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2017
First posted
Aug 15, 2017
StartActual
Dec 15, 2017
Primary completionActual
Jun 3, 2022
CompletionActual
Aug 24, 2022
Results first posted
Jun 24, 2024
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03250299
Responsible party
Sponsor
First posted
Aug 15, 2017
Start date
Dec 15, 2017
Primary completion
Jun 3, 2022
Completion
Aug 24, 2022
Results posted
Jun 24, 2024
Last update
Jun 24, 2024

Study contacts

Matthias Holdhoff, MD
study chair · National Cancer Institute (NCI)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisavanbulin

Start the discussion